GW501516 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-12 and is reviewed periodically as new material appears.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
acylation, e.g. O-acylation (esters), N-acylation (amides), S-acylation (thioesters) acetylation, the addition of an acetyl group, either at the N-terminus of the protein or at lysine residues. The reverse is called deacetylation. formylation alkylation, the addition of an alkyl group, e.g. methyl, ethyl methylation the addition of a methyl group, usually at lysine or arginine residues. The reverse is called demethylation. amidation at C-terminus. Formed by oxidative dissociation of a C-terminal Gly residue. monoaminylation, addition of monoamines to glutamine residues via transamidation dopaminylation, the addition of dopamine to glutamine residues via transamidation histaminylation, the addition of histamine to glutamine residues via transamidation serotonylation, the addition of serotonin to glutamine residues via transamidation amide bond formation amino acid addition arginylation, a tRNA-mediation addition polyglutamylation, covalent linkage of glutamic acid residues to the N-terminus of tubulin and some other proteins. (See tubulin polyglutamylase) polyglycylation, covalent linkage of one to more than 40 glycine residues to the tubulin C-terminal tail butyrylation gamma-carboxylation dependent on Vitamin K glycosylation, the addition of a glycosyl group to either arginine, asparagine, cysteine, hydroxylysine, serine, threonine, tyrosine, or tryptophan resulting in a glycoprotein. Distinct from glycation, which is regarded as a nonenzymatic attachment of sugars.
Since 1921, the Toronto Transit Commission (TTC) gradually expanded its public transportation network to Scarborough. Today, it operates bus and rapid transit routes in the district. Line 2 Bloor–Danforth has three subway stations in Scarborough: Victoria Park, Warden, and Kennedy, the current eastern terminus. In 1985, the Government of Ontario opened the Scarborough RT, an above-ground light metro line that operated between Kennedy station at its west and McCowan Road at its east. In 2023, the line shut down permanently due to aging Infrastructure which also caused a derailment earlier that year. Construction of an extension of Line 2 further east into Scarborough started in June 2021 and is expected to be complete around 2030. The line will be extended 7.8 kilometres from Kennedy station with stations at McCowan Road-Lawrence Avenue, Scarborough Centre, and McCowan Road-Sheppard Avenue. Opened in February 2026, Line 5 Eglinton is a light rail line with its eastern terminus at Kennedy station. The City of Toronto is also proposing another light rail line known as the Eglinton East LRT that is planned to operate from Kennedy station to the University of Toronto Scarborough. Seven rail stations also provide access to two commuter rail lines operated by GO Transit. The Lakeshore East line runs across the south end of the district with Rouge Hill GO Station, Guildwood GO Station, Eglinton GO Station, and Scarborough GO Station running from east to west.
In so doing Jesus had relied upon Christ, a synonym for Truth, Science and God, a power that Quimby believed all human beings could access. Quimby referred to this idea, in February 1863, as "Christian science," a phrase he used only once in writing. He wrote:
=== 3. Clinical Examples: CAL vs Pseudopocket vs Gingival Enlargement === Patients with clinical attachment loss typically present with features of chronic periodontitis. A common example is a middle-aged adult with deep true periodontal pockets, gingival recession, tooth mobility, furcation involvement, and radiographic evidence of alveolar bone loss. Another example includes localized attachment loss due to aggressive toothbrushing, presenting as cervical recession with exposed CEJ and true pocket formation. Key identifying features include irreversible attachment loss, apical migration of the JE, and true periodontal pocket formation. Pseudopockets are commonly seen in younger patients with plaque-induced gingivitis. For example, a teenager may present with swollen, edematous gingiva, probing depths of 6–10 mm, a hidden CEJ, and no radiographic bone loss. Similarly, patients with orthodontic brackets may develop localized gingival swelling around brackets, resulting in 5–7 mm probing depths without attachment loss. These cases are characterized by false pockets, increased probing depth due solely to gingival swelling, and reversibility with proper plaque control. Gingival enlargement presents differently depending on etiology. Drug-induced cases, such as in patients taking phenytoin or nifedipine, show bulbous, firm, bead-like gingiva with buried CEJs and minimal bleeding on probing. Hormonal enlargement, such as pregnancy epulis, appears as localized, red, soft, and friable gingival masses with partially hidden CEJs and increased sulcus depth.
== History == McLeod syndrome was discovered in 1961 and, similar to the Kell antigen system, was named after the first patient in which it was discovered; a Harvard dental student by the name of Hugh McLeod. McLeod's red blood cells demonstrated a peculiar appearance when viewed microscopically (acanthocytic (spiky)) and showed weak expression of Kell system antigens. A pattern of pregnancy loss and infant deaths associated with the wives of King Henry VIII of England suggests he may have been Kell-positive and had McLeod syndrome given his eventual premature mental deterioration.
Sources: en.wikipedia.org
== Industrial use == Butane-1,4-diol is used industrially as a solvent and in the manufacture of some types of plastics, elastic fibers and polyurethanes. In organic chemistry, 1,4-butanediol is used for the synthesis of γ-butyrolactone (GBL). In the presence of phosphoric acid and high temperature, it dehydrates to the important solvent tetrahydrofuran. At about 200 °C in the presence of soluble ruthenium catalysts, the diol undergoes dehydrogenation to form butyrolactone. It is used to synthesize 1,4-butanediol diglycidyl ether which is then used as a reactive diluent for epoxy resins. 1,4-Butanediol is used in the production of polybutylene terephthalate (PBT) plastic. World production of butane-1,4-diol was claimed to be about one million metric tons per year and market price is about US$2,000 (€1,600) per ton in 2005. In 2013, worldwide production was claimed to be billions of pounds (consistent with approximately one million metric tons). Almost half of it is dehydrated to tetrahydrofuran to make fibers such as Spandex. The largest producer is BASF.
== Prognosis == The median survival in idiopathic pulmonary fibrosis is 3–3.5 years. However, prognosis varies widely depending on the specific type and cause of ILD; some inflammatory forms may stabilize or improve with treatment. ILD is associated with a 3-fold increased risk of lung cancer. Life expectancy after lung transplant is 5.2 years in those with idiopathic interstitial pneumonias (including idiopathic pulmonary fibrosis) and 6.7 years in those with other types of ILD.
== Introduction == Isozymes were first described by R. L. Hunter and Clement Markert (1957) who defined them as different variants of the same enzyme having identical functions and present in the same individual. This definition encompasses (1) enzyme variants that are the product of different genes and thus represent different loci (described as isozymes) and (2) enzymes that are the product of different alleles of the same gene (described as allozymes). Isozymes are usually the result of gene duplication, but can also arise from polyploidisation or nucleic acid hybridization. Over evolutionary time, if the function of the new variant remains identical to the original, then it is likely that one or the other will be lost as mutations accumulate, resulting in a pseudogene. However, if the mutations do not immediately prevent the enzyme from functioning, but instead modify either its function, or its pattern of expression, then the two variants may both be favoured by natural selection and become specialised to different functions. For example, they may be expressed at different stages of development or in different tissues. Allozymes may result from point mutations or from insertion-deletion (indel) events that affect the coding sequence of the gene. As with any other new mutations, there are three things that may happen to a new allozyme:
In the Catholic Church, the Dicastery for the Causes of Saints, previously named the Congregation for the Causes of Saints (Latin: Congregatio de Causis Sanctorum), is the dicastery of the Roman Curia that oversees the complex process that leads to the canonization of saints, passing through the steps of a declaration of "heroic virtues" and beatification. After preparing a case, including the approval of miracles, the case is presented to the pope, who decides whether or not to proceed with beatification or canonization.
In the two crystal structures of normal human G6P, Pro172 is seen exclusively in the cis conformation, while in the crystal structure of one disease causing mutant (variant Canton R459L), Pro172 is seen almost exclusively in the trans conformation.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.